Alzheimer’s Disease Resources and References

1. Alzheimer’s Disease Fact Sheet. http://www.nia.nih.gov/alzheimers/publication/alzheimers-disease-fact-sheet. Accessed July 5, 2013.
2. What Is Alzheimer’s? http://www.alz.org/alzheimers_disease_what_is_alzheimers.asp. Accessed July 5, 2013.
3. Brookmeyer R, Johnson E. Forecasting the global burden of Alzheimer’s disease. Alzheimer’s Dement. 2007; 3(3):186-191.
4. Alzheimer’s Facts and Figures. http://www.alz.org/alzheimers_disease_facts_and_figures.asp. Accessed July 5, 2013.
5. Alzheimer’s disease. http://www.mayoclinic.com/health/alzheimers-disease/DS00161. Accessed July 5, 2013.
6. About Alzheimer’s http://www.alzfdn.org/AboutAlzheimers/definition.html. Accessed July 5, 2013.
7. Morrison AS,Lyketsos C. The pathophysiology of Alzheimer’s disease and directions in treatment. Adv Stud Nurs. 2005; 3 (8):256-270.
8. About Alzheimer’s Disease: Alzheimer’s Basics. http://www.nia.nih.gov/alzheimers/topics/alzheimers-basics#what. Accessed July 5, 2013.
9. Roe CM, Fagan AM, Grant EA, et al. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology. 2013; 80(19):1784-1791.
10. Alzheimer’s disease – Causes. http://www.nhs.uk/Conditions/Alzheimers-disease/Pages/Causes.aspx. Accessed July 5, 2013.
11. Mortality From Alzheimer’s Disease in the United States: Data for 2000 and 2010. http://www.cdc.gov/nchs/data/databriefs/db116.htm. Last accessed on July 24, 2013.
12. Risk Factors. http://www.alz.org/alzheimers_disease_causes_risk_factors.asp. Last accessed on July 24, 2013.
13. Erika J. Lampert, Kingshuk Roy Choudhury, et al. Prevalence of Alzheimer’s Pathologic Endophenotypes in Asymptomatic and Mildly Impaired First-Degree Relatives. PLoS ONE, 2013; 8 (4): e60747 DOI: 10.1371/journal.pone.0060747.
14. Risk Factors. http://www.alz.org/alzheimers_disease_causes_risk_factors.asp. Last accessed on July 24, 2013.
15. Gottlieb S. Head injury doubles the risk of Alzheimer’s disease. BMJ. 2000; 321(7269): 1100.
16. Flicker L. Modifiable lifestyle risk factors for Alzheimer’s disease. J Alzheimers Dis. 2010; 20(3):803-811.
17. Cataldo JK, Prochaska JJ. Cigarette smoking is a risk factor for Alzheimer’s Disease: an analysis controlling for tobacco industry affiliation. J Alzheimers Dis. 2010; 19(2):465-480.
18. Ott A, Scooter AJ. Smoking and risk of dementia and Alzheimer’s disease in a population-based cohort study: the Rotterdam Study. Lancet. 1998; 351(9119):1840-1843.
19. Rusanen M, Kivipelto M. Heavy smoking in midlife and long-term risk of Alzheimer’s disease and vascular dementia. Arch Intern Med. 2011; 171(4):333-339.
20. Merchant C, Tang MX. The influence of smoking on the risk of Alzheimer’s disease. Neurology. 1999; 52(7):1408-412.
21. Deborah E. Barnes, Kristine Yaffe. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. The Lancet Neurology. 2011; 10 (9): 819 – 828.
22. Radak Z, Hart N, Sarga L, et al. Exercise plays a preventive role against Alzheimer’s disease. J Alzheimers Dis. 2010; 20(3):777-783.
23. Scarmeas N, Luchsinger JA, Schupf N, et al. Physical activity, diet, and risk of Alzheimer’s disease. JAMA. 2009; 302(6):627-637.
24. The Role of Physical Activity in the Prevention and Management of Alzheimer’s Disease—Implications for Ontario. http://www.braininstitute.ca/sites/default/files/final_report_obi_pa_alzheimers_february_25_2013.pdf. Last accessed on July 24, 2013.
25. Tolppanen AM, Lavikainen P, Solomon A, etal.History of medically treated diabetes and risk of Alzheimer disease in a nationwide case-control study. Diabetes Care. 2013; 36(7):2015-2019.
26. Yang Y, Song W. Molecular links between Alzheimer’s disease and diabetes mellitus. Neuroscience. 2013. pii: S0306-4522(13)00584-8. doi: 10.1016/j.neuroscience.2013.07.009.
27. Moreira RO, Campos SC. Type 2 Diabetes Mellitus and Alzheimer’s Disease: from physiopathology to treatment implications. Diabetes Metab Res Rev. 2013. doing: 10.1002/dmrr.2442. [Epub ahead of print]
28. Nasal Insulin Spray Shows Promise In Treatment of Alzheimer’s. http://www.va.gov/opa/pressrel/pressrelease.cfm?id=2162. Last accessed on July 24, 2013.
29. Skoog I, Gustafson D.Update on hypertension and Alzheimer’s disease. Neurol Res. 2006; 28(6):605-611.
30. Maci T, PiraFL.Am Physical and cognitive stimulation in Alzheimer Disease. the GAIA Project: a pilot study. J Alzheimers Dis Other Demen. 2012; 27(2):107-113.
31. Bottino CM, Carvalho IA, Alvarez AM, et al. Cognitive rehabilitation combined with drug treatment in Alzheimer’s disease patients: a pilot study. ClinRehabil. 2005; 19(8):861-869.
32. Preventing Alzheimer’s Disease What Do We Know? National Institutes of Health National Institute on Aging. http://www.nia.nih.gov/alzheimers/publication/preventing-alzheimers-disease. Last accessed on July 24, 2013.
33. Holmes C, Cotterell D. Role of infection in the pathogenesis of Alzheimer’s disease: implications for treatment. CNS Drugs. 2009; 23(12):993-1002.
34. Wada H, Nakajoh K, Satoh-Nakagawa T. Risk factors of aspiration pneumonia in Alzheimer’s disease patients. Gerontology. 2001; 47(5):271-276.
35. Féart C, SamieriC.Potential benefits of adherence to the Mediterranean diet on cognitive health. ProcNutr Soc. 2013; 72(1):140-152.
36. Morris MC, Evans DA, Bienias JL, et al. Dietary fats and the risk of incident Alzheimer’s disease. Arch Neurol. 2003; 60(2):194-200.
37. Morris MC, Evans DA, Bienias JL. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer’s disease. Arch Neurol. 2003;60(7):940-946.
38. Alzheimer’s disease. http://www.nlm.nih.gov/medlineplus/ency/article/000760.htm. Last accessed on July 24, 2013.
39. Alzheimer’s disease. Complications. http://www.mayoclinic.com/health/alzheimers-disease/DS00161/DSECTION=complications. Last accessed on July 24, 2013.
40. Wada H, Nakajoh K, Satoh-Nakagawa T. Risk factors of aspiration pneumonia in Alzheimer’s disease patients. Gerontology. 2001; 47(5):271-276.
41. Maggio D, Ercolani S, Andreani S, etal.Emotional and psychological distress of persons involved in the care of patients with Alzheimer’s disease predicts falls and fractures in their care recipients. Dement GeriatrCognDisord. 2010;30(1):33-38.
42. Horikawa E, Matsui T. Risk of falls in Alzheimer’s disease: a prospective study. Intern Med. 2005; 44(7):717-721.
43. Kennedy.Proposed Revisions for the Diagnostic Categories of Dementia in the DSM-5. Primary Psychiatry. 2010; 17(5):26-28.EVIDENCE-BASED PSYCHOGERIATRICS
44. Highlights of Changes from DSM-IV-TR to DSM-5. http://www.psychiatry.org/dsm5. Accessed on July 31, 2013.
45. SiberskiJ. Dementia and DSM-5: Changes, Cost, and Confusion. Aging Well.2012; 5(6):12.
46. A Guide to DSM-5. Neurocognitive Disorder http://www.medscape.com/viewarticle/803884_13Accessed on July 31, 2013.
47. Ref: About Alzheimer’s Disease: Diagnosis. http://www.nia.nih.gov/alzheimers/topics/diagnosis#how. Accessed on July 31, 2013.
48. Roe CM, Fagan AM, Grant EA, et al. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology. 2013 May 7;80(19):1784-1791.
49. Doecke JD, Laws SM, Faux NG, et al. Blood-based protein biomarkers for diagnosis of Alzheimer’s disease. Arch Neurol. 2012; 69(10):1318-1325.
50. Jellinger KA, Janetzky B. Biomarkers for early diagnosis of Alzheimer disease: ‘ALZheimerASsociated gene’–a new blood biomarker? J Cell Mol Med. 2008;12(4):1094-1117.
51. Memory Loss and Confusion. http://www.alz.org/care/dementia-memory-loss-problems-confusion.asp#respond. Accessed August 27, 2013.
52. Caregiver Guide: Tips for Caregivers of People with Alzheimer’s Disease. http://www.nia.nih.gov/alzheimers/publication/caregiver-guide-tips-caregivers-people-alzheimers-disease. Accessed August 27, 2013.
53. Danucalov MAD, Kozasa EH. A Yoga and Compassion Meditation Program Reduces Stress in Familial Caregivers of Alzheimer’s Disease Patients. Evid Based Complement Alternat Med. 2013; 2013: 513149.
54. Support for Alzheimer’s and Dementia Caregivers. http://www.helpguide.org/elder/alzheimers_disease_dementia_support_caregiver.htm. Accessed August 27, 2013.
55. Prince M, Bryce R, et al. The global prevalence of dementia: a systematic review and meta-analysis. Alzheimer’s Dement. 2013; 9(1):63-75.e2).
56. Mathuranath PS, George A, Ranjith N, et al. Incidence of Alzheimer’s disease in India: a 10 years follow-up study. Neurol India. 2012; 60(6):625-630.
57. Prevalence of dementia in Europe. http://www.alzheimer-europe.org/Research/European-Collaboration-on-Dementia/Prevalence-of-dementia/Prevalence-of-dementia-in-Europe. Accessed September 3, 2013.
58. Alzheimer’s Facts and Figures. http://www.alz.org/alzheimers_disease_facts_and_figures.asp. Accessed September 3, 2013.
59. Anand R, Gill KD. Therapeutics of Alzheimer’s disease: Past, present, and future. Neuropharmacology. 2013 Jul 25. [Epub ahead of print].
60. About Alzheimer’s Disease: Treatment. http://www.nia.nih.gov/alzheimers/topics/treatment. Last assessed on August 29, 2013.
61. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006 ;( 1): CD005593.
62. Chu L. Alzheimer’s disease: early diagnosis and treatment. Hong Kong Med J 2012; 18:228-237.
63. Schmitt B, Bernhardt T. Combination therapy in Alzheimer’s disease: a review of current evidence. CNS Drugs. 2004; 18(13):827-844.
64. Tariot PN, Farlow MR. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004; 291(3):317-324.
65. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as a treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. N Engl J Med. 1997; 336(17):1216-1222.
66. Antipsychotic Medications Used to Treat Alzheimer’s Patients Found Lacking. http://www.nimh.nih.gov/news/science-news/2006/antipsychotic-medications-used-to-treat-alzheimers-patients-found-lacking.shtml. Last assessed on August 29, 2013.
67. Lilly Voluntarily Terminates Phase II Study for LY2886721, a Beta Secretase Inhibitor, Being Investigated as a Treatment for Alzheimer’s Disease. http://newsroom.lilly.com/releasedetail.cfm?ReleaseID=771353. Last assessed on August 29, 2013.
68. Ghosh AK, Brindisi M. Developing β-secretase inhibitors for the treatment of Alzheimer’s disease. J Neurochem. 2012; 120 Suppl 1:71-83.
69. Alzheimer’s disease: Current treatment options and future developments Rachel Flurie, PharmD candidate. Formulary. 2011; 46:268–284.
70. Drug Company Halts Development of γ-Secretase Inhibitor Avagacestat. http://www.alzforum.org/new/detail.asp?id=3344. Last assessed on August 29, 2013.
71. Weiner HL, Frenkel D. Immunology and immunotherapy of Alzheimer’s disease. Nat Rev Immunol. 2006; 6(5):404-416.
72. Major Step Toward an Alzheimer’s Vaccine. http://www.sciencedaily.com/releases/2013/01/130115143852.htm. Last assessed on August 29, 2013.
73. Advances in the Development of Vaccines for Alzheimer’s Disease. http://www.discoverymedicine.com/Doris-Lambracht-Washington/2013/05/27/advances-in-the-development-of-vaccines-for-alzheimers-disease/. Last assessed on August 29, 2013.
74. Tian J, Shi J. Herbal therapy: a new pathway for the treatment of Alzheimer’s disease. Alzheimer’s Res Ther. 2010; 2(5):30.
75. Brendan J. Alternative Medicine and Alzheimer’s Disease. Neurologist. 2008; 14(5): 299–306.
76. Janssen IM, Sturtz S. Ginkgo biloba in Alzheimer’s disease: a systematic review. Wien Med Wochenschr. 2010; 160(21-22):539-546.
77. Le Bars PL, Katz MM. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA. 1997 Oct 22-29; 278(16):1327-1332.
78. Xu SS, Gao ZX, Weng Z, et al. Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer’s disease. Zhongguo Yao Li XueBao. 1995; 16(5):391-395.
79. Zhang Z, Wang X. [Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial]. Zhonghua Yi XueZaZhi. 2002; 82(14):941-944.
80. Lee ST, Chu K. Panax ginseng enhances cognitive performance in Alzheimer disease. Alzheimer Dis Assoc Disord. 2008; 22(3):222-226.
81. Akhondzadeh S, Noroozian M. Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer’s disease: a double-blind, randomized and placebo-controlled trial. J Clin Pharm Ther. 2003; 28(1):53-59.
82. Morris MC, Evans DA, Bienias JL, et al. Dietary fats and the risk of incident Alzheimer’s disease. Arch Neurol. 2003; 60(2):194-200.
83. 25.Spagnoli A, Lucca U, Menasce G, et al. Long-term acetyl-L-carnitine treatment in Alzheimer’s disease. Neurology. 1991; 41(11):1726-1732.
84. Bianchetti A, Rossini R. Effects of acetyl-L-carnitine in Alzheimer’s disease patients unresponsive to acetylcholinesterase inhibitors. Curr Med Res Opin. 2003; 19(4):350-353.
85. Innis SM. Dietary (n-3) Fatty Acids and Brain Development. J. Nutr. April 2007; 137 (4): 855-859.
86. Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol. 2006; 63(10):1402-1408.
87. Morris MC, Evans DA, Bienias JL, et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol. 2003; 60(7):940-946.
88. Douaud G, Refsum H. Preventing Alzheimer’s disease-related gray matter atrophy by B-vitamin treatment. ProcNatlAcadSci U S A. 2013; 110(23):9523-9528.
89. Afzal S, Bojesen SE. Reduced 25-hydroxyvitamin D and risk of Alzheimer’s disease and vascular dementia. Alzheimer’s Dement. 2013. pii: S1552-5260(13)02425-4.
90. Grant WB. Does vitamin D reduce the risk of dementia? J Alzheimers Dis. 2009; 17(1):151-159.
91. Dietary Guidelines for Alzheimer’s Prevention. http://www.pcrm.org/health/reports/dietary-guidelines-for-alzheimers-prevention. Last assessed on August 29, 2013.
92. Lee SY. [The effect of lavender aromatherapy on cognitive function, emotion, and aggressive behavior of elderly with dementia]. TaehanKanhoHakhoe Chi. 2005; 35(2):303-312.
93. Jimbo D, Kimura Y. Effect of aromatherapy on patients with Alzheimer’s disease. Psychogeriatrics. 2009; 9(4):173-179.
94. Meditation. http://nccam.nih.gov/health/meditation/overview.htm?nav=gsa
95. Newberg AB, Wintering N. Meditation effects on cognitive function and cerebral blood flow in subjects with memory loss: a preliminary study. J Alzheimers Dis. 2010; 20(2):517-526.
96. Innes KE, Selfe TK. The Effects of Meditation on Perceived Stress and Related Indices of Psychological Status and Sympathetic Activation in Persons with Alzheimer’s Disease and Their Caregivers: A Pilot Study. Evid Based Complement Alternat Med. 2012; 2012: 927509.
97. Rowe M, Alfred D. The effectiveness of slow-stroke massage in diffusing agitated behaviors in individuals with Alzheimer’s disease. J GerontolNurs. 1999; 25(6):22-34.
98. Snyder M, Egan EC. Interventions for decreasing agitation behaviors in persons with dementia. J GerontolNurs. 1995; 21(7):34-40.
99. Fukui H, Arai A. Efficacy of music therapy in treatment for the patients with Alzheimer’s disease. Int J Alzheimers Dis. 2012;2012:531646.
100. Education and Care. http://www.alzfdn.org/EducationandCare/musictherapy.html. Last assessed on August 29, 2013.
101. Simmons-Stern NR, Budson AE. Music as a memory enhancer in patients with Alzheimer’s disease. Neuropsychologia. 2010; 48(10):3164-3167.
102. Manipal J. Psychosocial-Environmental Treatments for Alzheimer’s Disease. Primary Psychiatry. 2009; 16(6):39-47.
103. http://umm.edu/health/medical/altmed/condition/alzheimers-disease
104. Radak Z, Hart N, Sarga L, et al. Exercise plays a preventive role against Alzheimer’s disease. J Alzheimers Dis. 2010; 20(3):777-783.
105. Scarmeas N, Luchsinger JA, Schupf N, et al. Physical activity, diet, and risk of Alzheimer’s disease. JAMA. 2009; 302(6):627-637.
106. Qaseem A, Snow V, Cross JT Jr, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2008; 148(5):370-378.
107. NIH Consensus Development Conference Statement on Preventing Alzheimer’s Disease and Cognitive Decline. NIH Consensus and State-of-the-Science Statements Volume 27, Number 4 April 26–28, 2010.
108. Cat’s Claw. http://nccam.nih.gov/health/catclaw?nav=gsa. Accessed on September 10, 2013.
109. Xu Y, Cao Z. J Alzheimers Dis. 2008;13(3):341-349. Gotu Kola (Centella Asiatica) extract enhances phosphorylation of cyclic AMP response element binding protein in neuroblastoma cells expressing amyloid beta peptide.
110. Caltagirone C, Ferrannini L. The potential protective effect of tramiprosate (homotaurine) against Alzheimer’s disease: a review. Aging Clin Exp Res. 2012;24(6):580-587.
111. ActaBiochim Pol. 2011;58(4):513-20. Epub 2011 Dec 6. Neuroprotective effects of dehydroepiandrosterone (DHEA) in a rat model of Alzheimer’s disease.
112. Wiener JM, Tilly J. Population aging in the United States of America: implications for public programs.Int J Epidemiol. 2002; 31(4):776-781.
113. Kaneda. A Critical Window for Policymaking on Population Aging in Developing Countries. http://www.prb.org/Publications/Articles/2006/ACriticalWindowforPolicymakingonPopulationAginginDevelopingCountries.aspx. Assessed October 7, 2013.
114. Dementia and Alzheimer’s Care. http://www.helpguide.org/elder/alzheimers_disease_dementias_caring_caregivers.htm. Assessed October 8, 2013.

Resources